A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast Cancer

Cancer type: Ovarian cancer

Phase: II

Principal Investigator: Juhler-Nøttrup Trine

Country: DK

Keywords: Denmark, Herlev, karyopharm, KPT-330, selinexor, SIGN, ovarian cancer, endometrial cancer, cervical cancer, SINE, breast cancer, HER2 negative

Status: Completed

Link to